Foundation Medicine to develop companion diagnostic for Bristol Myers' cancer drug repotrectinib
hapabapa/iStock Editorial via Getty Images
- Foundation Medicine said it expanded collaboration with Bristol Myers Squibb (NYSE:BMY) to develop a tissue-based test FoundationOne CDx, as a companion diagnostic for Bristol Myers' investigational oral cancer drug repotrectinib.
- Repotrectinib, a tyrosine kinase inhibitor (TKI), is being evaluated in an ongoing phase 1/2 trial called TRIDENT-1 to treat patients with TKI-naive or TKI-pretreated ROS1+ advanced non-small cell lung cancer (NSCLC) and NTRK+ advanced solid tumors.
- If the companion diagnostic is approved for these uses, and if the therapy is approved, oncologists will be able to use FoundationOne CDx to help identify appropriate patients for treatment with repotrectinib.
- "We're proud to broaden our collaboration with Bristol Myers Squibb as they work to bring this exciting investigational therapy to patients living with ROS1 positive non-small cell lung cancer and NTRK positive solid tumors," said Jason Adams, vice president of Biopharma Enterprise Partnerships, Foundation Medicine.
- Bristol Myers inherited repotrectinib via a $4.1B acquisition of Turning Point Therapeutics.